BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Aerpio Therapeutics 

9987 Carver Road
Suite 420
Cincinnati  Ohio  45242  U.S.A.
Phone: 513-985-1920 Fax: 513-985-0999


SEARCH JOBS



Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.

Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.

The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.


 Key Statistics


Email:
Ownership: Private

Web Site: Aerpio
Employees: n/a
Symbol: 
 



Industry
Biotechnology






 Company News
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema 12/4/2014 9:41:42 AM
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Aerpio Announces Publication Of Preclinical Data On AKB-9778 For Common Eye Diseases 9/3/2014 12:48:40 PM
Aerpio Presents Full Results From Phase 1b/2a Study Of AKB-9778 For The Treatment Of Diabetic Macular Edema At Association for Research in Vision & Ophthalmology Annual Meeting 5/5/2014 9:54:32 AM
Aerpio Closes $22 Million Financing 4/23/2014 8:31:02 AM
Aerpio Initiates Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Diabetic Macular Edema 2/13/2014 9:12:37 AM
Aerpio Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension 11/6/2013 10:13:55 AM
Aerpio Announces Publication of Data on Tie2 Activator, AKB-9778, Supporting Future Clinical Development in Cancer 8/5/2013 9:39:45 AM
Aerpio Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema 9/19/2012 10:06:25 AM
Aerpio Raises $27 Million 8/31/2012 7:49:03 AM
12